[Cat. No.] ATS-0006, ATS-0007, ATS-0008

Introduction

Active RNA-Guided Endonucleases (aRGENs) are ready-to-use guide RNAs for your genome editing experiments. AccuTool™ aRGENs positive controls have validated guide RNA sequences, and they are verified to be highly genome editing efficient. When combined with suitable Cas9 mRNA (optional) or recombinant Cas9 protein (optional), aRGENs will form ready-for-action to genome engineering. The reagents can be used for in vitro and in vivo without additional processing.

Applications

- Genome editing
- Drug discovery: CRISPR library screening, target validation
- Bioprocessing: Cell line engineering
- Agriculture: Plant breeding

Components

-	
Components	Amount
Lyophilized sgRNA (aRGEN)	2 nmol
Lyophilized Forward primer	1 nmol
Lyophilized Reverse primer	1 nmol
DEPC-treated water	1 ml

* Note: For research use only. Not for use in diagnostic or therapeutic procedures.

Reconstitution of Ivophilized saRNA

- Dissolve lyophilized guide RNA in DEPC-treated water.
- Recommended concentration of stock guide RNA solution.

For animal embryo injection	1-2 µg/µl
For in vitro digestion study	1-2 µg/µl
For genome engineering in cultured cells	5 µg/µl

Storage

- AccuTool[™] aRGENs positive controls are lyophilized and delivered at ambient temperature.
- Store lyophilized RNAs or reconstituted RNA stock solutions at or below -20°C. Do not store in a frost-free freezer.

Precautions

- As RNA oligonucleotides (aRGENs) are highly susceptible to degradation by exogenous RNase that may be introduced during the handling steps, all the steps must be conducted under sterile. RNase-free conditions.
- RNase-free reagents, pipette tips, and tubes must be used with gloved hands while handling them.

Online Resources





Visit our product page for additional information and protocols.

Ordering Information

Description	Cat. No.
AccuToo/™ Positive control_EGFP sgRNA (aRGEN)	ATS-0006
AccuToo/™ Positive control_CCR5 sgRNA (aRGEN)	ATS-0007
AccuToo/™ Positive control_HPRT1 sgRNA (aRGEN)	ATS-0008

Notice

BIONEER corporation reserves the right to make corrections, modifications, improvements and other changes to its products, services, specifications or product descriptions at any time without notice

Explanation of Symbols



REF Catalog



Temperature Use-by Limitation Date

Copyright 2021 BIONEER Corporation. All Rights Reserved.

BQ-042-101-04 Revision : 7 (2021-04-12)

Experimental Procedures

	Steps	Procedure Details				
Dig	estion of target sequence i	n vitro using CRISPR sgR	IAs			
	× 1	1. Set up the reaction mixture as below.				
		Components	Amount			
	- T- T	Cas9 Protein	500 ng	(100-1,000 ng)		
1		CRISPR sgRNA	250 ng	(100-700 ng)		
· .		Targeting substrate	100-150 ng	PCR product		
			80 ng	(Plasmid)		
	Decementian of econtion	10X Reaction buffer	1 µl			
	Preparation of reaction mixture	D.W.	Το 10 μl			
2	Incubation of reaction	 Incubate the reaction mixture at 37°C for 1 hr. Add 4 μg of RNase and incubate for 15 min at 37°C. Add 1 μl of STOP solution to the reaction mixture and incubate for 15 min at 37°C. [STOP solution: 30% glycerol, 1.2% SDS, 250 mM EDTA (pH 8.0)] Analyze on 2% agarose gel. 				
	mixture					
	of reagents up or down accordingly. 1. Add Cas9 RNP complex (0.5 µg of Cas9 Nuclease and 250 ng of CRISPR sgRNA) to 50 µ Opti-MEM I Reduce Serum Medium.					
2. In a separate tube, dilute the transfection reagent by addir transfection reagent to 50 µl of Opti-MEM I Reduce Serum						
1	6	3. Incubate for 5 min at room te	emperature.			
		 Add the diluted transfection reagent to the tube containing Cas9 protein/gRNA RNP complexes and mix gently. 				
	Preparation of transfection reagent	Incubate at room temperature for 20 min to allow the formation of Cas9/gRNA-lipid complexes.				
	Th	6. Add the Cas9/gRNA-lipid complexes to the 1x10 ⁵ NIH3T3 cells to be transfected. Swirl the plates gently to allow the mixing of the transfection mixture with the medium.				
2	Cell transfection			n a cell culture incubator for 2-3 days, editing efficiency by T7E1 assay or		
	(!)	Refer to the electroporation method for highly efficient transfection only.				
	Option					

Copyright 2021 BIONEER Corporation. All Rights Reserved.

2 www.bioneer.com

BQ-042-101-04 Revision : 7 (2021-04-12)